课题基金 / 基金详情

Calcification Propensity, using Dynamic Light Scattering, to Study Vascular Calcification in Patients with Advanced Chronic Kidney Disease

Calcification Propensity, using Dynamic Light Scattering, to Study Vascular Calcification in Patients with Advanced Chronic Kidney Disease
使用动态光散射研究晚期慢性肾病患者的血管钙化倾向
批准号:
10418310
负责人:
Wei Chen
金额:
$16.16万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-08-01 至 2023-03-31

项目摘要

项目成果

Wei Chen的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/摘要 本提案的目的是促进Wei Chen,MD,MS作为独立的 具有研究慢性肾脏病患者血管钙化(VC)专业知识的翻译研究员 病(CKD)。CKD患者的VC患病率较高,这导致他们的心血管疾病发病率较高。 发病率和死亡率。在某种程度上,由于缺乏有效的VC生物标志物,目前还没有有效的 治疗以减缓其进展。最近,开发了一种血清测定来测量钙化倾向, 它可能作为VC的生物标志物,指导新疗法的开发。但不清楚 通过该测定测量的钙化倾向与VC之间是否存在直接关系。博士 Chen将通过研究钙化倾向与VC严重程度的关系来解决这个问题 以及导致VC的细胞机制。与生物化学家本杰明米勒博士(顾问),博士。 Chen开发了一种新的基于微孔板的检测方法,该方法使用动态光散射。他们的初步数据 证明了新的检测方法与旧的检测方法相比,对VC的预测能力更高, 使用浊度法。使用改进的检测方法,Chen博士将检验以下2个假设:1)血液透析 具有较高钙化倾向的患者冠状动脉钙化更严重, 与倾向性较低的患者相比,动脉硬化和全因和心血管死亡率较高; 和2)较高的钙化倾向与动脉RNA表达较高的相关因子有关 在血管平滑肌细胞骨软骨形成中,包括runt相关转录因子-2(runx 2)和 骨钙素第一个假设将在417名接受血液透析的患者中进行检验, 终末期肾病患者心律失常和心血管风险研究。为了验证第二个假设,博士。 Chen将招募100名正在接受动静脉通路创建手术的CKD患者, 血清钙化倾向,并获得术中动脉样本(每例患者每次活检3- 5 mm), 测量runx 2和骨钙素的动脉RNA表达。这项建议将作出重大贡献 旨在验证一种新的VC生物标志物,为VC的病理生理学提供新的见解, 有可能指导新的治疗策略,以降低CKD患者的死亡率。创新是因为 博士Chen和她的团队采用了一种新的检测方法和一种翻译方法来研究VC。另外这款 建议书将为陈博士提供实现其培训目标的机会, 进行风险投资研究的知识和技能,以及实施药物临床试验质量管理规范 纵向数据分析和临床研究设计。陈博士与她一起制定了这些培训目标 多学科的指导团队,并完成这些目标是必不可少的陈博士实现她的 长期职业目标。该K23奖项将支持拟议的培训和职业发展活动, 让陈博士成为一名独立的翻译研究者。
英文摘要
PROJECT SUMMARY/ABSTRACT The purpose of this proposal is to foster the development of Wei Chen, MD, MS as an independent translational researcher with the expertise to study vascular calcification (VC) in patients with chronic kidney disease (CKD). CKD patients have a high prevalence of VC, which contributes to their high cardiovascular morbidity and mortality. In part, due to the absence of a valid biomarker for VC, there is currently no effective treatment to slow its progression. Recently, a serum assay was developed to measure calcification propensity, and it may serve as a biomarker for VC to guide development of new therapies. However, it is unknown whether there is a direct relationship between calcification propensity, as measured by this assay, and VC. Dr. Chen will address this question by examining the association of calcification propensity with the severity of VC and the cellular mechanism leading to VC. In conjunction with a biochemist—Dr. Benjamin Miller (advisor), Dr. Chen developed a new, microplate-based assay that uses dynamic light scattering. Their preliminary data demonstrated that the new assay may have a greater predictive power for VC compared to the old assay that used nephelometry. Using the improved assay, Dr. Chen will test the following 2 hypotheses: 1) hemodialysis patients with higher calcification propensity have greater coronary arterial calcification, a faster progression of arterial stiffness and higher all-cause and cardiovascular mortality compared to those with lower propensity; and 2) higher calcification propensity is associated with higher arterial RNA expression of the factors involved in vascular smooth muscle cell osteochondrogenesis, including runt-related transcription factor-2 (runx2) and osteocalcin. The first hypothesis will be tested in 417 patients on hemodialysis from the Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease study. To test the second hypothesis, Dr. Chen will recruit 100 CKD patients that are undergoing arteriovenous access creation surgeries, measure serum calcification propensity, and obtain intraoperative arterial samples (3-5mm per biopsy per patient) to measure arterial RNA expression of runx2 and osteocalcin. This proposal will make a significant contribution towards validating a novel VC biomarker, provide new insights into the pathophysiology of VC and has the potential to guide new treatment strategies to reduce mortality in patients with CKD. It is innovative because Dr. Chen and her team employ a novel assay and a translational approach to study VC. In addition, this proposal will provide opportunities for Dr. Chen to achieve her training objectives, which are to acquire knowledge and skills in conducting VC research, implementation of Good Clinical Laboratory Practice as well as longitudinal data-analyses and clinical study design. Dr. Chen developed these training objectives with her multidisciplinary mentoring team, and accomplishing these objectives is essential for Dr. Chen to achieve her long-term career goal. This K23 award will support the proposed training and career development activities, and allow Dr. Chen to become an independent translational researcher.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI: 10.3390/ijms25021155
发表时间: 2024-01-18
期刊: International journal of molecular sciences
影响因子: 5.6
作者: []
通讯作者:
An ensemble deep learning model for tumor bud detection and risk stratification in colorectal carcinoma.
  • 批准号:
    10564824
  • 项目类别:
  • 资助金额:
    $54.37万
  • 财政年份:
    2023
  • 负责人:
    Wei Chen
  • 依托单位:
Establishing translational neuroimaging tools for quantitative assessment of energy metabolism and metabolic reprogramming in healthy and diseased human brain at 7T
  • 批准号:
    10714863
  • 项目类别:
  • 资助金额:
    $63.02万
  • 财政年份:
    2023
  • 负责人:
    Wei Chen
  • 依托单位:
SCH: New Advanced Machine Learning Framework for Mining Heterogeneous Ocular Data to Accelerate
SCH: New Advanced Machine Learning Framework for Mining Heterogeneous Ocular Data to Accelerate
海外基金